NASDAQ:VCYT

Veracyte Stock Forecast, Price & News

$53.20

+2.30 (+4.52 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$51.32

Now: $53.20▼

$53.46

50-Day Range

$34.66

MA: $42.81▼

$51.88

52-Week Range

$13.90

Now: $53.20▼

$53.46

Volume248,700 shs

Average Volume511,696 shs

Market Capitalization$3.08 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.62

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Veracyte has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $40.83, Veracyte has a forecasted downside of 23.2% from its current price of $53.20.
Amount of Analyst Coverage
Veracyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Veracyte has received 381 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Veracyte has received 245 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Veracyte has received 60.86% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote “Outperform” if you believe VCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Veracyte does not currently pay a dividend.
Dividend Growth
Veracyte does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,726,443.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Veracyte is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Veracyte are expected to grow in the coming year, from ($0.77) to ($0.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veracyte is -84.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veracyte is -84.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veracyte has a P/B Ratio of 10.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VCYT

Previous Symbol

CUSIPN/A

CIK1384101

Webwww.veracyte.com

Phone650-243-6300

Employees354

Debt

Debt-to-Equity RatioN/A

Current Ratio13.18

Quick Ratio12.64

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$120.37 million

Price / Sales25.59

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.90 per share

Price / Book10.86

Profitability

EPS (Most Recent Fiscal Year)($0.27)

Net Income$-12,600,000.00

Net Margins-27.49%

Return on Equity-13.35%

Return on Assets-11.68%

Miscellaneous

Outstanding Shares57,897,000

Market Cap$3.08 billion

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$53.20

+2.30 (+4.52 %)

(As of 11/27/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

How has Veracyte's stock been impacted by Coronavirus?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VCYT shares have increased by 125.9% and is now trading at $53.20.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Veracyte?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Veracyte or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Veracyte?

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Veracyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Veracyte.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Monday, November, 2nd. The biotechnology company reported ($0.08) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.13. Veracyte had a negative net margin of 27.49% and a negative return on equity of 13.35%.
View Veracyte's earnings history.

What price target have analysts set for VCYT?

7 equities research analysts have issued 1 year target prices for Veracyte's shares. Their forecasts range from $35.00 to $48.00. On average, they anticipate Veracyte's share price to reach $40.83 in the next twelve months. This suggests that the stock has a possible downside of 23.2%.
View analysts' price targets for Veracyte.

Who are some of Veracyte's key competitors?

Some companies that are related to Veracyte include Guardant Health (GH), Invitae (NVTA), Natera (NTRA), Elekta AB (publ) (EKTAY), Burning Rock Biotech (BNR), CareDx (CDNA), Genetron (GTH), Personalis (PSNL), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Renalytix AI (RNLX), DermTech (DMTK), Centogene (CNTG) and Exagen (XGN).
View all competitors.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Who are Veracyte's key executives?

Veracyte's management team includes the following people:

Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 62, Pay $1.16M)
Mr. Keith S. Kennedy C.F.A., CPA, CFA, CPA, CFO & COO (Age 50, Pay $866.97k)
Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 61, Pay $677.7k)
Mr. John Walter Hanna Jr., Chief Commercial Officer (Age 40, Pay $583.3k)
Mr. Mark Ho, Principal Accounting Officer (Age 47)
Mr. Ashish Kheterpal, Chief Information Officer
Ms. Tracy Morris, VP of Corp. Communications & Investor Relations
Mr. James H. Erlinger III, Exec. VP, Gen. Counsel & Sec. (Age 62)
Ms. Jessica Meng, VP of Marketing
Dr. Alfred Bowie Jr., VP of Corp. & Bus. Devel.

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.88%), William Blair Investment Management LLC (9.81%), BlackRock Inc. (8.86%), Nikko Asset Management Americas Inc. (5.91%), State Street Corp (3.77%) and GW&K Investment Management LLC (2.10%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte.

Which institutional investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Allianz Asset Management GmbH, Nikko Asset Management Americas Inc., First Trust Advisors LP, State Street Corp, AQR Capital Management LLC, Victory Capital Management Inc., and Grandeur Peak Global Advisors LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, Kevin K Gordon, Mark Ho, and Robert S Epstein.
View insider buying and selling activity for Veracyte.

Which institutional investors are buying Veracyte stock?

VCYT stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, William Blair Investment Management LLC, BlackRock Inc., Morgan Stanley, Oak Ridge Investments LLC, Perkins Capital Management Inc., Caas Capital Management LP, and Clough Capital Partners L P.
View insider buying and selling activity for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $53.20.

How big of a company is Veracyte?

Veracyte has a market capitalization of $3.08 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 354 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings